Cardiac-specific overexpression of cyclin-dependent kinase 2 increases smaller mononuclear cardiomyocytes

被引:0
|
作者
Liao, HS [1 ]
Kang, PM [1 ]
Nagashima, H [1 ]
Yamasaki, N [1 ]
Usheva, A [1 ]
Ding, B [1 ]
Lorell, BH [1 ]
Izumo, S [1 ]
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Cardiovasc Div, Boston, MA 02215 USA
关键词
cardiomyocyte regeneration; cell cycle; cyclin-dependent kinase;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cyclin-dependent kinase 2 (cdk2) plays a critical role in the G1- to S-phase checkpoint of the cell cycle. Adult cardiomyocytes are believed to withdraw from the cell cycle, To determine whether forced overexpression of cdk2 results in altered cell-cycle regulation in the adult heart, we generated transgenic mice specifically overexpressing cdk2 in hearts. Transgenic hearts expressed high levels of both cdk2 mRNA and catalytically active cdk2 proteins. Cdk2 overexpression significantly increased the levels of cdk4 and cyclins A, D3, and E. There was an increase in both DNA synthesis and proliferating cell nuclear antigen levels in the adult transgenic hearts. The ratio of heart weight to body weight in cdk2 transgenic mice was significantly increased in neonatal day 2 but not in adults compared with that of wild-type mice. Analysis of dispersed individual adult cardiomyocytes showed a 5.6-fold increase in the proportion of smaller mononuclear cardiomyocytes in the transgenic mice. Echocardiography revealed that transgenic heart was functionally normal. However, adult transgenic ventricles expressed beta -myosin heavy chain and atrial natriuretic factor. Surgically induced pressure overload caused an exaggerated maladaptive hypertrophic response in transgenic mice but did not change the proportion of mononuclear cardiomyocytes. The data suggest that overexpression of cdk2 promotes smaller, less-differentiated mononuclear cardiomyocytes in adult hearts that respond in an exaggerated manner to pressure overload.
引用
收藏
页码:443 / 450
页数:8
相关论文
共 50 条
  • [21] Role for cyclin-dependent kinase 2 in mitosis exit
    D'Angiolella, V
    Costanzo, V
    Gottesman, ME
    Avvedimento, EV
    Gautier, J
    Grieco, D
    CURRENT BIOLOGY, 2001, 11 (15) : 1221 - 1226
  • [22] Differential and dramatic changes of cyclin-dependent kinase activities in cardiomyocytes during the neonatal period
    Kang, MJ
    Koh, GY
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1997, 29 (07) : 1767 - 1777
  • [23] A BRAIN-SPECIFIC ACTIVATOR OF CYCLIN-DEPENDENT KINASE-5
    LEW, J
    HUANG, QQ
    QI, Z
    WINKFEIN, RJ
    AEBERSOLD, R
    HUNT, T
    WANG, JH
    NATURE, 1994, 371 (6496) : 423 - 426
  • [24] Cellular effects of purvalanol A: A specific inhibitor of cyclin-dependent kinase activities
    Villerbu, N
    Gaben, AM
    Redeuilh, G
    Mester, J
    INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (06) : 761 - 769
  • [25] Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
    Cui, Heying
    Loftus, Kyle M.
    Noell, Crystal R.
    Solmaz, Sozanne R.
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2018, (135):
  • [26] Identification of Potential Phytochemicals Against Cyclin-Dependent Kinase 1 and Cyclin-Dependent Kinase 2: A Molecular Docking and Molecular Dynamic Approach
    Pawar, Swaranjali
    Shinde, Shalini
    Chavan, Pooja
    Rathod, S.
    Choudhari, P.
    Arvindekar, Snehal
    Patil, S.
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 86 (01) : 322 - 329
  • [27] Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
    Chen, YNP
    Sharma, SK
    Ramsey, TM
    Jiang, L
    Martin, MS
    Baker, K
    Adams, PD
    Bair, KW
    Kaelin, WG
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) : 4325 - 4329
  • [28] Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression
    Smalley, Keiran S. M.
    Contractor, Rooha
    Nguyen, Thiennga K.
    Xiao, Min
    Edwards, Robin
    Muthusamy, Viswanathan
    King, Alastair J.
    Flaherty, Keith T.
    Bosenberg, Marcus
    Herlyn, Meenhard
    Nathanson, Katherine L.
    CANCER RESEARCH, 2008, 68 (14) : 5743 - 5752
  • [29] Rux is a cyclin-dependent kinase inhibitory (CKI) specific for mitotic cyclin-Cdk complexes
    Foley, E
    O'Farrell, PH
    Sprenger, F
    CURRENT BIOLOGY, 1999, 9 (23) : 1392 - 1402
  • [30] Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A
    Schulman, BA
    Lindstrom, DL
    Harlow, E
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (18) : 10453 - 10458